Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
Scientists at the University of Cologne have developed a new inducible expression system, which is easy to use, reliable and very fast. The System is based on…
The therapeutic use of dendritic cells in vaccination
therapy requires prior activation of these immune
…
A novel fermentation method for fed-batch operating
conditions, based on microtiterplates (MTPs) was developed at the Dept. of Biochemical Engineering, RWTH…
Scientists at the RWTH Aachen have identified new
peptides which can be used for the prevention of
atherosclerosis or in the treatment of…
Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)
which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine.
The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of
viral latency. Mutant virus infected B-lymphocytes died after the productive phase….
Invention
Scientists at the University of Münster, Germany, have isolated and characterized a novel substance class from Cocoa. CocoaHeal is capable of…